Reckitt Benckiser (india) Private Limited

Reckitt Benckiser (India) Private Limited, established on July 5, 1951, is a subsidiary of Reckitt Benckiser Group plc, a British multinational consumer goods company. The company is registered in Haryana, India, with its corporate identification number (CIN) U74999HR1951PTC075277. Its registered office is located at DLF Cyber Park, 6th & 7th Floor (Tower C), 405 B, Udyog Vihar Phase III, Sector 20, Gurgaon, Haryana, 122016.

As of April 4, 2024, Reckitt Benckiser (India) Private Limited employed 1,772 individuals. The company's authorized capital is ₹100 crore, with a paid-up capital of ₹100 crore, indicating a robust financial foundation.

Reckitt Benckiser (India) Private Limited operates manufacturing facilities in various locations, including Hosur, Tamil Nadu. The Hosur plant is situated in the SIPCOT Industrial Complex, near the ESI Bus Stop, Hosur, Tamil Nadu, 635126. While specific details regarding the capacities and specializations of these facilities are not publicly disclosed, the company's extensive product portfolio suggests a well-equipped manufacturing infrastructure capable of producing a diverse range of pharmaceutical formulations.

The leadership team of Reckitt Benckiser (India) Private Limited includes:

• Gaurav Jain: Managing Director

• Rajesh Kumar Jha: Additional Director

• Chander Mohan Sethi: Director

These executives play pivotal roles in steering the company's strategic direction and operations.

Reckitt Benckiser (India) Private Limited's products are subject to regulatory oversight in key markets such as the United States, European Union, United Kingdom, Australia, and Japan. While specific details regarding regulatory filings, approvals, and market access status are not publicly available, the company's association with Reckitt Benckiser Group plc, a globally recognized entity, suggests adherence to international regulatory standards. This affiliation likely facilitates smoother market entry and compliance with regulatory requirements in these regions.

Reckitt Benckiser (India) Private Limited has a presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's products, such as Dettol and Disprin, are well-established in these regions, indicating a strong market penetration. While specific details regarding WHO prequalification are not available, the company's global footprint and product acceptance suggest compliance with international quality standards, facilitating access to these markets.

Reckitt Benckiser (India) Private Limited demonstrates a diversified geographic strategy by exporting to various international markets. This approach mitigates concentration risk and leverages growth opportunities across different regions. The company's strategic direction appears focused on expanding its global presence while maintaining a strong foothold in the domestic market.

Specific details regarding Reckitt Benckiser (India) Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the company's association with Reckitt Benckiser Group plc, a globally recognized entity, suggests adherence to international regulatory standards, including those set by the FDA.

While specific information regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certificates for Reckitt Benckiser (India) Private Limited is not publicly available, the company's global operations and product acceptance in various markets imply compliance with international quality standards. This adherence likely includes WHO prequalification and EU GMP certifications, facilitating access to these markets.

Reckitt Benckiser (India) Private Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company's products are approved by state drug controllers, and it possesses the necessary export No Objection Certificates (NOCs), facilitating international trade.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Reckitt Benckiser (India) Private Limited. This absence suggests a favorable regulatory standing and adherence to compliance standards.

In the analgesics and over-the-counter (OTC) products segment, Reckitt Benckiser (India) Private Limited faces competition from companies such as Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Ltd., and Lupin Ltd. Reckitt's market leadership in products like Disprin, Aspirin, and Salicylic acid underscores its strong competitive position. The company's focus on brand names and OTC products, comprising 58.6% of its portfolio, further solidifies its standing in the market.

Reckitt Benckiser (India) Private Limited's key differentiators include its strong brand portfolio, with market-leading products such as Disprin, Aspirin, and Salicylic acid. The company's focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, distinguishes it from competitors dealing with raw active pharmaceutical ingredients (APIs). This specialization allows Reckitt to offer comprehensive therapeutic solutions to consumers.

Reckitt Benckiser (India) Private Limited's current strategic direction emphasizes the production and export of finished pharmaceutical formulations, particularly in the analgesics and OTC segments. The company's future outlook likely involves expanding its product portfolio, enhancing manufacturing capabilities, and exploring new markets to sustain growth and maintain its competitive edge.

Reckitt Benckiser (India) Private Limited has a commendable track record in the pharmaceutical industry, with a total export value of $28.5 million USD and 2,032 shipments across five products in three therapeutic categories. The company's portfolio concentration, with the top five products accounting for 100% of exports, indicates a focused and reliable supply chain. The absence of recent regulatory actions further underscores the company's reliability and commitment to quality.

Importers should verify the following certifications when engaging with Reckitt Benckiser (India) Private Limited:

• FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

• WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practices, ensuring product quality and safety.

• EU GMP Certification: Ensure the company holds European Union Good Manufacturing Practice certification, facilitating access to European markets.

• ISO Certification: Check for relevant International Organization for Standardization certifications, indicating adherence to international quality standards.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from the company.

When conducting due diligence on Reckitt Benckiser (India) Private Limited, consider the following steps:

• Verify Regulatory Compliance: Confirm the company's certifications, including FDA, WHO-GMP, EU GMP, and ISO, to ensure adherence to international standards.

• Assess Financial Health: Review the company's financial statements and credit history to evaluate its financial stability.

• Evaluate Supply Chain Reliability: Assess the consistency and reliability of the company's supply chain, considering its portfolio concentration and export history.

• Review Legal Standing: Check for any legal disputes, charges, or regulatory actions that may impact the company's operations.

• Conduct Site Visits: If possible, visit the company's manufacturing facilities to assess operational standards and quality control measures.

Be vigilant for any discrepancies in certifications, financial irregularities, or legal issues that may pose risks. Engaging with reputable third-party auditors or consultants can provide additional assurance during the due diligence process.